A Phase I, Double-blind, Randomised, Single-dose, Parallel Group Study to Demonstrate the Equivalent Pharmacokinetic Properties of a Single Intravenous Dose of HD204 and Bevacizumab (Avastin) in Healthy Male Subjects
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Apr 2018
At a glance
- Drugs HD-204 (Primary) ; Bevacizumab
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Prestige BioPharma
- 03 Apr 2018 Planned End Date changed from 1 Apr 2018 to 1 Nov 2018.
- 03 Apr 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Oct 2018.
- 03 Apr 2018 Planned initiation date changed from 1 Jan 2018 to 1 Jun 2018.